The Immense Cost of Non-Adherence
.png)
Financial implications
he financial implications of non-adherence in clinical development are substantial.
• Up to $36,000 in direct cost per lost patient
• Approximately $1.6 million in potential revenue impact for each day of delayed market authorization
• 67% of protocol deviations linked to adherence-related issues
Recruitment is expensive.
Replacing drop-outs is even more so.
Beyond direct costs, non-adherence introduces secondary risks:
- Delayed database lock
- Extended monitoring
- Increased site workload
- Regulatory scrutiny
Adherence is not merely an operational issue, it is a financial exposure.
Beyond Trials: The Broader Healthcare Burden
Non-adherence does not stop at clinical trials.
In real-world care:
- Up to 70% of patients may be non-adherent to complex regimens
- Approximately 200,000 avoidable deaths occur annually in the EU due to non-adherence
- €125 billion in unnecessary healthcare costs are attributed to avoidable hospitalizations and emergency care in Europe
- In the U.S., non-optimized medication therapy costs between $495–673 billion annually
Absenteeism and productivity loss further amplify the societal burden.
Poor adherence increases inpatient costs, emergency visits, and chronic disease complications.
The scale of the problem makes one thing clear:
Adherence is not peripheral.
It is central to healthcare sustainability.
Managing adherence proactively reduces financial exposure.
Learn how ARM introduces structured adherence risk governance.
.jpg)
